UNSPSC 51434963: Valsartan/Sacubitrilo

Sacubitril/valsartan is a drug for chronic heart failure (CHF)

UNSPSC 51434963 Valsartan/Sacubitrilo is a Commodity code representing a specific pharmaceutical product, but the recent state and local opportunities tagged under this code show little to no direct procurement activity for valsartan/sacubitrilo itself. Of the sixteen records in the opportunity block, only one—Seminole County, Florida's solicitation for Naloxone and Safe Drug Deactivation Systems (IFB60459723LAS, due July 26, 2026)—involves pharmaceutical procurement, and it targets opioid-emergency response products, not cardiovascular medications. The remaining opportunities span unrelated domains: Tucson Fire Department's BLS/ALS pharmaceuticals and vending systems; forensic drug standards for Pinellas County; employee wellness clinic services in Collier County; MHSA peer support services in San Mateo County; municipal vendor forums and reverse trade shows; and cooperative purchasing platforms for generic pharmaceuticals nationwide. The mismatch between the code's nominal scope and actual recent solicitation activity suggests that state and local governments either purchase valsartan/sacubitrilo through standing agreements or cooperative contracts rather than direct RFP/RFQ activity, or that procurement systems have tagged opportunities with this code in error.

No issuing bodies show repeated procurement of valsartan/sacubitrilo specifically. Activity appears concentrated in Florida (Seminole County, Pinellas County, Collier County, Marion County, Indian River County, and statewide FAPPO) and Arizona (Tucson), with secondary presence in Texas (Williamson County), California (San Mateo), Arkansas (Little Rock), and Minnesota cooperative purchasing. The one pharmaceutical-procurement notice actually posted—Seminole County's naloxone acquisition—reflects emergency-response priorities unrelated to this code's cardiovascular focus. State and local procurement of branded or generic valsartan/sacubitrilo compounds typically flows through GPOs, state health plan formularies, Medicaid managed-care contracts, or cooperative purchasing vehicles rather than discrete solicitations; this code shows no evidence of active direct-buy opportunities at present.